U.S. Infrastructure Stock News

Lithia Motors (LAD) is back in the spotlight after Lithia & Driveway secured a place on the Fortune Global 500 for the second year, moving to No. 426 and reinforcing its expanding automotive retail footprint. See our latest analysis for Lithia Motors. The Fortune Global 500 recognition arrives at a time when Lithia Motors’ share price has gained 14.25% over the past 30 days and 35.33% over 90 days, while its 1 year total shareholder return sits at 22.08%. This points to building momentum...

American Superconductor recently reported stronger sales and net income for its first quarter of 2026, and management issued guidance for the second quarter calling for revenue above US$85 million and net income above US$1 million, signaling an expectation of continued profitability. The results and outlook are underpinned by robust demand from semiconductor and data center customers, while several valuation models continue to suggest the shares trade below estimated intrinsic value. We’ll...

Novavax, Inc. recently reported its second-quarter 2026 results, with revenue of US$56.7 million versus US$239.24 million a year earlier and a net loss of US$53.39 million compared with net income of US$106.51 million. Over the first half of 2026, revenue dropped to US$196.21 million from US$905.90 million, while results swung from net income of US$625.15 million to a loss of US$62.88 million, sharply reversing the company’s prior profitability. We’ll now examine how this sharp...

Agilent Technologies (A) is back in focus after being highlighted as a key supplier to the expanding cannabis testing services market, along with a favorable analyst rank that points to improving earnings expectations and renewed investor interest. See our latest analysis for Agilent Technologies. The recent focus on Agilent Technologies as a key provider to cannabis testing services has coincided with a 19.31% 1 month share price return and a 35.39% 90 day share price return. The 1 year...

PENN Entertainment (PENN) has announced plans to invest about US$195 million to shift its Boomtown Casino & Hotel New Orleans operations to a new landside site and rebrand the venue as Hollywood Casino New Orleans. See our latest analysis for PENN Entertainment. The New Orleans project comes after a busy period for PENN Entertainment, with the stock showing an 11.14% 90 day share price return and a 24.98% year to date share price return, although the 1 year total shareholder return is...

ScanSource (SCSC) is back on investors’ radar after the company announced the retirement of long serving director Peter C. Browning, which coincided with a 3.7% drop in the stock. See our latest analysis for ScanSource. The recent 3.7% intraday drop came on top of a 5.2% decline in ScanSource’s 30 day share price return, although the 90 day share price return of 20.45% and 1 year total shareholder return of 20.90% still point to positive momentum overall. If this kind of governance news has...

Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations so far, and outlined plans to start a rolling FDA New Drug Application in the first quarter of 2027 and complete it by the third quarter of 2027. This smoother-than-expected enrollment, together with the clean retention profile, may strengthen confidence in the trial’s execution as the company...

Coherent (COHR) is back in focus after reporting record revenue and margin expansion tied to AI data center optical connectivity, along with plans for higher capital spending and capacity growth that introduce fresh execution questions for investors. See our latest analysis for Coherent. The share price reaction has been volatile, with Coherent falling 6.19% on the day and 19.17% over the past week, yet still showing a 47.93% year to date share price return and very large multi year total...

Einride stock jumped 5.4% to $6.04 after its half year 2026 report, even as the headline story remains the strain on the balance sheet. The company is still generating losses, with basic earnings per share for the period at 17.85 SEK in the red and trailing twelve month losses near 78.77 SEK per share. That sits against a rich 16.1x price to sales multiple and a cash runway flagged as under one year. For investors, today’s move is less about a clean turnaround and more about how long the...

In the past few days, Phillips 66 reported that second-quarter adjusted earnings rose by almost triple year over year as refining margins roughly doubled amid wartime supply disruptions and tight global refining capacity, while the company advanced projects like the Western Gateway pipeline and continued paying down debt and returning cash to shareholders. An interesting angle is that Western Gateway’s primarily 10-year take-or-pay contracts are intended to lock in more predictable midstream...

Why Air Products and Chemicals Stock Is Back in Focus Sustained analyst optimism after recent positive earnings has put Air Products and Chemicals (APD) back on many investors’ watchlists, even as high capital spending, project exit charges, and helium pricing pressure remain front and center. See our latest analysis for Air Products and Chemicals. After a stronger run year to date, with a 21.1% share price return and a last close of $303.22, Air Products and Chemicals’ move has been more...

How IDACORP Stock Has Been Performing IDACORP (IDA) has drawn investor attention after recent trading left the stock about 4% lower over the past month, while total return over the past year remains about 14%. See our latest analysis for IDACORP. At a latest share price of US$140.76, IDACORP has seen recent momentum cool, with the 30-day share price return down 4.3%, even as the 1-year total shareholder return sits at about 14%. This points to a stock where long-term holders have still been...

Tempus AI (TEM) stock is in focus after CellCarta Inc. added the company as the second commercial laboratory partner in its CDx Commercialization Lab Network for oncology companion diagnostics. See our latest analysis for Tempus AI. The CellCarta agreement has arrived alongside a sharp shift in momentum for Tempus AI, with the share price up 24.09% over the last day and a 30 day share price return of 26.52%, yet the 1 year total shareholder return has declined 16.42%. This suggests that...

Canadian Solar (NasdaqGS:CSIQ) is back in focus after a key legal overhang was removed. A long running U.S. patent infringement dispute with Maxeon Solar has now been resolved fully in Canadian Solar's favor. See our latest analysis for Canadian Solar. The legal win arrives as Canadian Solar's share price reacts sharply in the short term, with a 1 day share price return of 7.06% and a 30 day share price return of 3.82%, while the year to date share price return is down 37.90% and the 3 year...

Pfizer (NYSE:PFE) has reached a settlement program intended to resolve a major portion of federal Depo-Provera intracranial meningioma lawsuits. The program targets a substantial share of more than 6,200 pending cases, with estimates that around 5,000 claims could be resolved under the agreement. The settlement is a potentially material legal development that may influence Pfizer’s litigation reserves, risk profile, and public perception. For a broader view of how large pharmaceutical and...

Acadia Realty Trust (AKR) drew investor attention after extending a US$75 million loan to BTF Whitestone LLC to acquire and redevelop the Whitestone Shopping Center in Queens, a grocery anchored retail property. See our latest analysis for Acadia Realty Trust. Over the past year, Acadia Realty Trust has combined relatively muted recent share price moves with stronger longer term outcomes, with a 1 year total shareholder return of 14.18% and a 3 year total shareholder return of 66.73%. The...

In recent months, Crown Castle has been contending with a higher-for-longer interest rate backdrop while restructuring its balance sheet and reducing debt, even as a bankruptcy claim tied to tenant DISH Wireless introduces additional uncertainty. This combination of financing pressures and customer-related legal risk directly affects how secure Crown Castle’s cash flows may appear to investors and lenders. Next, we’ll examine how the interest rate pressure and DISH-related bankruptcy...

Earlier this month, Eli Lilly and Company committed to deploy Veeva Vault CRM globally as part of Veeva’s Vault CRM Suite supporting agentic commercial workflows. This global rollout by a major pharmaceutical company highlights growing interest in AI-enabled commercial tools like Veeva’s Agentic Call Report to help generate commercial evidence. We’ll now examine how Eli Lilly’s global Vault CRM commitment could influence Veeva’s investment narrative, especially around AI‑driven commercial...

Axon Enterprise has delivered a very strong 246.4% return over the past 5 years, yet the latest valuation checks suggest the stock may now be pricing in a lot of optimism. The Discounted Cash Flow (DCF) intrinsic value estimate points to a premium to current fundamentals, while market based multiples look roughly in line with peers and the broader checks lean expensive. Over the past 5 years, Axon Enterprise has returned 246.4%, which puts long term holders in a strong position and raises...

KBR recently announced that its Mission Technology Solutions business, set to become Trinzic after a planned spin-off, secured new multi-year NATO and U.S. Army contracts worth up to about US$268 million alongside a regular US$0.165 quarterly dividend, while Kellogg Brown & Root LLC was chosen for a USTDA-backed green ammonia Pre-FEED project in Morocco. Together, these defense awards and low-carbon ammonia design work highlight how KBR’s mission-tech spin-off and technology licensing...

AbCellera Biologics (ABCL) drew fresh attention after reporting that its investigational antibody ABCL635 met primary efficacy endpoints in a Phase 2 trial for menopausal vasomotor symptoms, with statistically significant benefits versus placebo. See our latest analysis for AbCellera Biologics. Alongside the ABCL635 data, AbCellera Biologics has attracted fresh attention, with a 30 day share price return of 107.07% and a year to date share price return of 250.15%. The 1 year total shareholder...

With U.S. government debt now above $40b and Treasury yields at levels last seen before the global financial crisis, the cost of money is back in the spotlight. That shift can reshape which stocks benefit from higher rates and which feel pressure on valuations. This article looks at three stocks from a higher rate focused screener that appear particularly exposed to this move in markets and explains what that could mean for your portfolio. The stocks highlighted below are just a starting...

With the Fed minutes hinting that another rate hike is still on the table and inflation data hovering above the 2% target, short term cash and bond products linked to these decisions are back in the spotlight. This creates potential openings for investors watching short duration yields and money markets. This article first unpacks the backdrop, then walks through three stocks from our U.S. short duration and cash focused screener that appear positively exposed to this news. The stocks covered...

Exponent (EXPO) has caught investor attention after its recent share price move, with the stock up 3.6% over the past week and about 11.5% over the past month based on provided data. See our latest analysis for Exponent. Zooming out, Exponent’s recent 90 day share price return of 22.52% contrasts with a year to date share price move that is roughly flat. The 3 year and 5 year total shareholder returns show declines, which suggests momentum has picked up only in the shorter term as investors...